If you’re searching for bone marrow transplant ICD-10 definitions, approaches, and advances, you likely need specific procedure and diagnosis codes — or you’re trying to understand how transplant coding works in clinical practice. Here’s the short version: bone marrow and stem cell transplant procedures are coded under ICD-10-PCS (Procedure Coding System) using root operations like “Transfusion” (section 3, found in codes beginning with 30243), while the diseases that lead to transplant — leukemia, aplastic anemia, myelodysplastic syndromes — each have their own ICD-10-CM diagnostic codes.
But coding a bone marrow transplant correctly goes far beyond plugging in a single number. The type of transplant (autologous vs. allogeneic), the stem cell source (bone marrow, peripheral blood, cord blood), and the conditioning regimen all influence which codes apply. Getting this wrong creates billing denials, audit flags, and inaccurate outcome tracking. Let’s break it all down.
What Is a Bone Marrow Transplant?
A bone marrow transplant — more accurately called a hematopoietic stem cell transplant (HSCT) — replaces damaged or destroyed marrow with healthy stem cells capable of regenerating the blood-forming system. Over 50,000 HSCTs are performed worldwide each year, according to the Worldwide Network for Blood and Marrow Transplantation.
The procedure is used to treat conditions where the bone marrow either fails (aplastic anemia), becomes malignant (leukemia, lymphoma, myeloma), or produces defective cells (sickle cell disease, thalassemia). It’s also increasingly used in certain autoimmune diseases.
Key ICD-10 Codes for Bone Marrow Transplant
ICD-10-PCS Procedure Codes
In the ICD-10-PCS system, bone marrow and stem cell transplants fall under Section 3 (Administration), not the surgical section. This catches many coders off guard. The root operation is “Transfusion” — defined as putting in blood or blood products.
| Code | Description | Key Details |
|---|---|---|
| 30243G0 | Autologous bone marrow transfusion, percutaneous, central vein | Patient’s own marrow |
| 30243G1 | Allogeneic (nonautologous) bone marrow transfusion, percutaneous, central vein | Donor marrow (related or unrelated) |
| 30243X0 | Autologous cord blood stem cell transfusion, percutaneous, central vein | Patient’s stored cord blood |
| 30243X1 | Allogeneic cord blood stem cell transfusion, percutaneous, central vein | Donor cord blood |
| 30243Y0 | Autologous hematopoietic stem cell transfusion (peripheral blood) | Collected via apheresis |
| 30243Y1 | Allogeneic hematopoietic stem cell transfusion (peripheral blood) | Donor peripheral stem cells |
The 7th character distinguishes autologous (0) from allogeneic/nonautologous (1) — a critical distinction for reimbursement and outcomes tracking.
ICD-10-CM Diagnostic Codes Leading to Transplant
| Code | Condition | Approx. % of All HSCTs |
|---|---|---|
| C91.0x | Acute lymphoblastic leukemia (ALL) | ~12% |
| C92.0x | Acute myeloid leukemia (AML) | ~20% |
| C90.0x | Multiple myeloma | ~25% (mostly autologous) |
| C83-C85 | Non-Hodgkin lymphomas | ~18% |
| D61.1-D61.9 | Aplastic anemia | ~5% |
| D57.x | Sickle cell disorders | ~2% (growing) |
| D46.x | Myelodysplastic syndromes | ~8% |
Don’t forget the Z94.81 code — “Bone marrow transplant status” — which should be assigned on every subsequent encounter after transplant. This status code drives long-term follow-up documentation and surveillance coding.
Autologous vs. Allogeneic: Two Fundamentally Different Approaches
Autologous transplant uses the patient’s own stem cells, collected before high-dose chemotherapy. It carries lower complication rates (transplant-related mortality around 2-5%) but no graft-versus-tumor effect. It’s the standard approach for multiple myeloma and certain lymphomas.
Allogeneic transplant uses donor cells — from a matched sibling, unrelated donor, or haploidentical (half-matched) family member. Transplant-related mortality is higher (10-30% depending on donor match and conditioning), but the donor immune system can attack residual cancer cells through the graft-versus-leukemia (GVL) effect. This is the preferred approach for AML, ALL, MDS, and aplastic anemia.
- Matched sibling donor: Best outcomes, available to roughly 30% of patients
- Matched unrelated donor (MUD): Found through registries like Be The Match; outcomes approaching sibling-matched results
- Haploidentical donor: Any biological parent, child, or sibling is a half-match — dramatically expanding donor availability, especially for minority patients
- Cord blood: Allows greater HLA mismatch tolerance but slower engraftment
Recent Advances Changing the Field
Post-Transplant Cyclophosphamide (PTCy)
This single advance has arguably done more to expand transplant access than anything in the past two decades. By giving cyclophosphamide on days +3 and +4 after transplant, haploidentical transplants now achieve outcomes comparable to matched unrelated donor transplants — with significantly lower rates of chronic graft-versus-host disease (GVHD). Multiple studies show chronic GVHD rates dropping from 40-60% to 10-15%.
CAR-T Cell Therapy as a Bridge or Alternative
CAR-T therapy (coded under ICD-10-PCS as XW033C3 for tisagenlecleucel or XW033C7 for axicabtagene ciloleucel) is increasingly used as a bridge to transplant or, in some cases, a replacement for it in relapsed/refractory ALL and large B-cell lymphoma.
Reduced-Intensity Conditioning (RIC)
Older patients — previously excluded from transplant — can now undergo allogeneic HSCT using reduced-intensity or non-myeloablative conditioning regimens. The upper age limit has effectively shifted from 55 to 75+ at many centers, with patients over 60 now representing the fastest-growing transplant demographic.
Gene Therapy for Non-Malignant Diseases
For sickle cell disease and beta-thalassemia, gene therapy (e.g., lovotibeglogene autotemcel/Lyfgenia, exagamglogene autotemcel/Casgevy) is emerging as an alternative to allogeneic transplant, eliminating the need for a donor entirely.
Common Signs and Symptoms Leading to Transplant Evaluation
- Persistent fatigue, pallor, and dyspnea (anemia — hemoglobin often < 8 g/dL)
- Recurrent or severe infections (neutropenia — ANC < 500 cells/μL)
- Easy bruising, petechiae, or mucosal bleeding (thrombocytopenia — platelets < 20,000/μL)
- Relapsed or refractory malignancy after standard chemotherapy
- Bone marrow biopsy showing > 20% blasts (diagnostic threshold for acute leukemia)
Frequently Asked Questions
What is the ICD-10 code for bone marrow transplant status?
Z94.81 — “Bone marrow transplant status.” This code should be used on all encounters after a patient has received any type of hematopoietic stem cell transplant. It alerts providers to unique risks including GVHD, immunosuppression, and secondary malignancies.
Is bone marrow transplant coded as a surgical procedure in ICD-10-PCS?
No. Despite feeling very much like a “procedure,” HSCT is coded under Section 3 (Administration) with the root operation “Transfusion” — not under the Medical and Surgical section. The actual infusion of stem cells is, technically, an IV infusion. The bone marrow harvest from a donor is coded as a surgical procedure (07DP for iliac bone marrow aspiration).
What’s the difference between ICD-10-CM and ICD-10-PCS for transplant coding?
ICD-10-CM covers diagnoses (why the transplant is needed — e.g., C92.00 for AML). ICD-10-PCS covers procedures (what was done — e.g., 30243G1 for allogeneic bone marrow transfusion). Both are needed for complete inpatient documentation. Outpatient settings use CPT codes instead of PCS.
How long does it take to engraft after a bone marrow transplant?
Engraftment — defined as ANC > 500 for three consecutive days — typically occurs at day +14 to +21 for bone marrow and peripheral blood stem cells, and day +21 to +35 for cord blood transplants. Platelet engraftment (> 20,000 without transfusion) usually follows 1-2 weeks later.
What is the survival rate after bone marrow transplant?
It varies enormously by disease, stage, donor type, and patient age. For a patient with AML in first complete remission receiving a matched sibling transplant, 5-year overall survival is approximately 60-70%. For relapsed/refractory disease, it drops to 20-30%. Autologous transplant for myeloma carries 5-year survival rates exceeding 70%.
When to Consult a Transplant Specialist
Referral to a transplant center should happen early — ideally at diagnosis for high-risk acute leukemias, not after multiple relapses. Specific triggers for referral include:
- Newly diagnosed AML or ALL with high-risk cytogenetics (e.g., complex karyotype, Philadelphia chromosome-like ALL)
- Relapsed or refractory lymphoma or myeloma after second-line therapy
- Severe aplastic anemia in patients under 40 with a matched sibling donor
- Transfusion-dependent myelodysplastic syndrome with IPSS-R intermediate or higher risk
- Symptomatic sickle cell disease with recurrent vaso-occlusive crises despite hydroxyurea
The National Marrow Donor Program (Be The Match) recommends initiating donor searches at diagnosis for any patient who might need an allogeneic transplant — the search process alone takes an average of 3-4 months.
